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INTRODUCTION Background
Because of a 4-fold increase in opioid prescriptions since 1999, long-term opioid use has become major public health issues in the United States. 1, 2 Because opioids are frequently prescribed to patients discharged from emergency departments (EDs), it is important to understand the relationship between ED opioid prescribing for opioidnaive individuals and their risk of progressing to recurrent opioid use. 3 Some policymakers and members of the public perceive EDs to be a significant source of overprescription of opioids. [4] [5] [6] This perception may stem from the fact that many ED visits involve chronic or acute pain; adult patients reported pain as the primary symptom in 45% of ED visits. 7 With so many patients in pain, it is not surprising that recent studies have found that 17% to 21% of all ED discharges included a prescription for opioids. 4, 8 Importance
Despite the public health consequences of nonmedical and long-term prescription opioid use, [9] [10] [11] [12] short-term use of these medications is clinically indicated in select settings. 13, 14 With some rare exceptions, health care professionals do not intend for an initial opioid prescription issued for an acute pain episode to result in indefinite repeated prescriptions.
Editor's Capsule Summary
What is already known on this topic Dependency is a risk of opioid pain management.
What question this study addressed
In opioid-naive patients, are emergency department (ED) prescriptions more or less likely to progress to long-term opioid use than those from other clinical settings?
What this study adds to our knowledge In this claims database of 5.2 million prescriptions in opioid-naive patients, opioid prescriptions written in the ED-compared with other locations-were of lesser dose and duration, and were approximately half as likely to lead to long-term use.
How this is relevant to clinical practice
Opioid prescriptions from the ED appear less likely to lead to long-term use than those from other clinical settings.
progression of intended short-term use to an unintended prolonged pattern of use, 16, 17 which may occur in 1.5% to 27% of opioid-naive patients after they receive an initial prescription. [18] [19] [20] [21] [22] [23] [24] [25] This is critically important because intentional short-term use is emerging as a previously underrecognized segue to unintended prolonged opioid use. [16] [17] [18] [19] [20] [21] [22] [24] [25] [26] One of the 5 key questions proposed in the 2016 Centers for Disease Control and Prevention (CDC) guideline for prescribing opioids for chronic pain was to determine the effects of opioid therapy for acute pain on long-term opioid use. 27 The goal of these guidelines is to improve opioid prescribing practices to ensure patients have access to safer treatment while reducing the risks of nonmedical use and overdose.
Limited research has been conducted to date on prescribing practices for acute pain that limit risk of longterm opioid use. Current recommendations are to prescribe the lowest effective dose and quantity needed for the expected duration of pain. With new guidelines and ED clinicians facing the challenge of patients seeking help for uncontrolled pain, it is natural to ask whether and how prescribing in the ED compares with that in other settings. The guidelines were not published until after the study period; our goal in using their recommendations is not to determine the adherence rates to the CDC guidelines per se, but rather to use them as a source of reasonable and evidence-based standards for comparing prescriptions attributed to different settings.
Goals of This Investigation
We used administrative claims data to compare characteristics of opioid prescriptions written for opioid-naive patients discharged from the ED and other settings and evaluated the risk of long-term use of prescription opioids by addressing these questions: To what extent are opioid prescriptions issued to opioid-naive patients in the ED or non-ED settings concordant with best practices on the number of days supplied, the daily dose of the prescription, and the number of prescriptions filled for longacting or extended-release formulations? For opioid-naive patients, what is the difference in the rate of progression to long-term opioid use after an initial prescription in the ED compared with a non-ED setting?
MATERIALS AND METHODS
We adhered to the Reporting of Studies Conducted Using Observational Routinely-Collected Health Data statement. 28 
Study Design and Setting
We conducted an analysis of administrative claims data from January 1, 2009, through December 31, 2015 , from the OptumLabs Data Warehouse, a database composed of privately insured and Medicare Advantage enrollees throughout the United States; more than 35 million unique people had both medical and prescription drug coverage at some time during the study period. 29 OptumLabs Data Warehouse contains longitudinal health information on enrollees from geographically diverse regions across the United States, with the greatest representation from the Southern and Midwestern states. 30 It includes adjudicated claims for all health care services incurred by beneficiaries and submitted to the insurance company for payment. The included plans provide coverage for professional, facility, laboratory, and pharmacy claims. Administrative data include beneficiary sex, race or ethnicity, age, and dates of coverage. Medical claims include International Classification of Diseases, Ninth Revision (ICD-9) and ICD-10 procedure and diagnosis codes, Healthcare Common Procedure Coding System procedure codes, site of service codes, and provider specialty codes. 31 The commercial population covered by OptumLabs Data Warehouse is similar to the US population of commercially insured people in age, race or ethnicity, and sex. Further detail is provided in Appendix E1 (available online at http://www.annemergmed.com).
This study was determined to be exempt from review by the Mayo Clinic Institutional Review Board.
We identified opioid prescriptions filled between January 1, 2009, and December 31, 2015, by beneficiaries of all ages who had both medical and pharmacy coverage. To focus our attention on people for whom long-term opioid use is an important risk, we examined claims in the 3 months before each opioid fill and excluded prescription fills by beneficiaries who had either any hospice claims or at least 2 physician visits with a cancer diagnosis in those 3 months. (See Appendix E2, available online at http:// www.annemergmed.com, for codes used to identify cancer and hospice beneficiaries.)
We focused on opioid prescription fills among opioid-naive beneficiaries, defined as having no opioid fills in the previous 6 months. As such, we excluded fills for beneficiaries with less than 6 months of insurance enrollment before the index fill and those who had any opioid fills during those 6 months. We limited our cohort to the first opioid-naive fill for each beneficiary-the index fill. Our final cohort consists of 5.2 million index fills. A cohort flow chart is provided in Figure 1 .
We identified National Drug Codes for all opioids available during any part of the study period. For this study, we classified tramadol as an opioid. The complete list of medications classified as opioids for this study is provided in Appendix E3, available online at http://www. annemergmed.com.
We used conversion factors provided by the CDC to convert the daily prescribed opioid dose to milligrams of morphine equivalents. 32 Prescriptions written for 1,000 mg of morphine equivalents or more per day were excluded from the analysis (n¼22,607; 0.04% of opioid fills by people with medical and prescription coverage) as extreme outliers.
If multiple doses of the same opioid were filled on the same day with the same prescriber identification, we merged those fills and calculated a combined daily dose in milligrams of morphine equivalents. In rare cases (N¼56,845 beneficiaries and 114,507 opioid-naive fills), beneficiaries filled prescriptions for multiple different opioids or the same opioid with different prescribers on the same day. In these cases, each fill was included separately in the analysis. For this reason, the opioid fill is the unit of analysis rather than the beneficiary. Complete details are provided in Appendix E4, available online at http://www. annemergmed.com.
We used information from medical claims in the 30 days before and including the date of the index fill to determine the most likely source of the prescription. Detailed information is provided in Appendix E5, available online at http://www.annemergmed.com. We classified the most likely source of each index fill as ED visit only; non-ED visit only, which combines inpatient, outpatient, ambulatory surgery, and dental or accidental dental; and unknown source, which includes prescriptions in which both ED and non-ED services were provided on the same day (4.3% of all prescriptions), as well as prescriptions for which there was no medical claim in the 30 days leading up to and including the prescription fill date. A substantial proportion of prescriptions had no visits in the previous 30 days: 22% for the commercial population and 10% for the Medicare population; this rate is similar to that of a study using a different source of commercial claims, which found 28% of opioid fills unmatched, with a look-back period of 2 weeks. 33 Some of these prescriptions were likely written by dentists, who have been estimated to write 6.4% of opioid prescriptions. 34 We did not observe most dental visits because dentistry is not included in medical insurance benefits. In our sample of fills to opioid-naive patients, 7.0% of fills with a known prescriber specialty were written by a dentist or dental specialist. We present the results for prescriptions with unknown source throughout, but do not focus on the interpretation of this group of prescriptions.
All patients in the study were opioid naive, with no insurance-paid opioid fills in the previous 6 months, which decreases the variability in the dose and duration of opioids that would be considered appropriate. It is likely that, regardless of the setting, people receiving a new opioid prescription with no previous recent fills were either experiencing acute pain or were experiencing an acute exacerbation of a chronic problem. Appropriate prescribing practices for acute pain or acute exacerbations of chronic problems are likely similar across settings.
Administrative information was used to determine beneficiary age, race or ethnicity, sex, and type of insurance (commercial versus Medicare). We used type of insurance and beneficiary age to identify 3 key patient populations: commercially insured of all ages (commercial), people eligible for Medicare because of age (aged Medicare), and people with Medicare coverage who were younger than 65 years but qualified for Medicare because of long-term disability, end-stage renal disease, or other serious conditions (disabled Medicare).
To assess patient illness burden, we used the Elixhauser comorbidity measures, a set of 31 measures indicating presence of comorbidities associated with increased risk of mortality. 35 We used ICD-9 and ICD-10 codes to identify these comorbidities in the 6 months before the index fill. 36 We required a diagnosis to be present on 1 inpatient stay or 2 separate outpatient visits. Each index fill was categorized with flags for the Elixhauser comorbidities and whether the beneficiary had any claims in the 6 months before the fill.
Outcome Measures
We assessed concordance with best practice in opioid prescribing as summarized in the CDC guidelines. 27 One recommendation states that for acute pain, "[t]hree days or less will often be sufficient; more than seven days will rarely be needed." The number of days supplied was extracted from the pharmacy claim. We coded binary variables for prescriptions for more than 3 days and more than 7 days' supply.
Another recommendation states that physicians should write prescriptions for the lowest effective dose. For patients using opioids for chronic pain, the CDC urged caution if increasing doses to greater than 50 mg of morphine equivalents per day; doses greater than 90 mg of morphine equivalents per day were suggested to be appropriate only for pain specialists to prescribe. Binary variables indicated whether an index fill was written for more than 50 or more than 90 mg of morphine equivalents per day. Because these would be exceptionally high doses for opioid-naive patients, we expected to identify a small proportion of fills in this dose range.
A third recommendation from the guideline states that extended-release or long-acting opioids should not be used when opioid therapy is started. We anticipated that prescriptions for extended-release and long-acting formulations would be rare in a cohort of opioid-naive patients.
To determine the risk of long-term use of opioids, we examined opioid fills in the 12 months after the index fill. Long-term opioid use was defined with the Consortium to Study Opioid Risks and Trends criteria: episodes of opioid prescribing lasting longer than 90 days and 120 or more total days' supply or 10 or more prescriptions in the year after the index fill. 37 Only beneficiaries with at least 12 months of continuous enrollment after the index fill were included in this analysis. Because this analysis was performed on a different population than the analyses of guideline concordance (which was allowed to have less than 12 months of follow-up), we repeated all guideline concordance analyses using just the cohort with at least 12 months of follow-up. We found no difference in the results of these analyses. A full comparison of results is presented in Appendix E11, available online at http://www. annemergmed.com.
Primary Data Analysis
Distributions of demographic and fill characteristics were compared with c 2 goodness-of-fit tests, one-way ANOVA, and a Wald test for equality of coefficients after Poisson regression; see Appendix E7, available online at http://www.annemergmed.com, for further details. We report 95% confidence intervals (CIs) for selected results in the text; all CIs are presented in tables or appendices.
Logistic regression was used to measure the association between the source of the initial prescription and study outcomes. Prescription source (ED, non-ED, and unknown) was interacted with beneficiary type (commercial, aged Medicare, and disabled Medicare) in the model. Covariates included year (continuous), age, age squared, age cubed, female sex, race or ethnicity, indicators for each Elixhauser comorbidity, and whether the beneficiary had any medical claims in the 6 months before the fill. Complete results from logistic regression models are provided in Appendix E8, available online at http://www.annemergmed.com. Adjusted probabilities of outcomes were calculated for each beneficiary type and prescription source. Risk ratios were generated from these probabilities, with 95% confidence intervals calculated with the delta method. 38 Stata/MP (version 14.2; StataCorp, College Station, TX) was used for all analyses. 39 We performed a supplementary analysis treating time as a categorical variable to allow estimation of time trends in the proportion of prescriptions concordant with guidelines. Results are described briefly in the text and presented in full in Appendix E11, available online at http://www.annemergmed.com.
RESULTS
We identified 5,241,948 naive opioid fills that met inclusion criteria ( Table 1 ). The rate of naive opioid fills per person-year was similar across the 3 populations, with 0.07 naive fills per person-year for the commercial, 0.07 for the aged Medicare, and 0.06 for the disabled Medicare populations (difference significant at P<.001, but a minor clinical difference). We report the total opioid fills per person-year (including both naive and non-naive fills, and including buprenorphine and methadone fills) for context. Although the rates of opioid-naive fills were similar across the 3 groups, the disabled Medicare population filled 7.15 total opioid prescriptions per person-year, 4 times more than the aged Medicare population and 8 times more than the commercial population.
Main Results
The proportion of prescriptions attributed to the ED was 11.7% in aged Medicare, 13.3% in commercial, and 17.4% in the disabled Medicare populations ( Table 1 ). The most common medication prescribed for naive fills across all treatment settings was hydrocodone (composing 58.9% of commercial fills, 49.2% of aged Medicare, and 49.7% of disabled Medicare) ( Table 1) .
Guideline concordance of prescriptions is reported in Tables 1 and 2 and in Figure 2A to F. Unadjusted rates of guideline concordance by beneficiary population are reported in Table 1 , adjusted rates of concordance by beneficiary population and treatment setting (ED, non-ED, and unknown) in Table 2 , and adjusted risk ratios in Figure 2A to F. A table of risk ratios with 95% confidence intervals is provided in Appendix E10, available online at http://www.annemergmed.com.
It was common for opioid-naive beneficiaries to fill prescriptions exceeding 3 days' supply, with unadjusted proportions ranging from 57.4% among commercial to 68.0% among disabled Medicare beneficiaries ( (Figure 2A) .
Prescriptions from the ED were also less likely to exceed 7 days' supply compared with non-ED prescriptions. In the ED, adjusted proportions of prescriptions exceeding 7 days were 84% to 91% lower than in the non-ED setting (adjusted risk ratio comparing ED to non-ED was 0. 16 Table 2 ; risk ratios in Figure 2B ).
Prescriptions for high doses of milligrams of morphine equivalents were common; 17.0% to 19.9% exceeded 50 mg of morphine equivalents per day, and 5.2% to 6.0% exceeded 90 mg of morphine equivalents per day (unadjusted proportions; see Table 1 for details). Prescriptions from the ED were 23% to 37% less likely to exceed 50 mg of morphine equivalents ( Figure 2C ; regression adjusted) and 33% to 54% less likely to exceed 90 mg of morphine equivalents than those attributed to non-ED settings ( Figure 2D ; regression adjusted).
Prescriptions for long-acting or extended-release formulations were rare among opioid-naive beneficiaries, with unadjusted percentages ranging from 0.5% of commercial to 1.9% of disabled Medicare prescriptions.
In the regression-adjusted analysis, prescriptions from the ED were 86% to 92% less likely to be written for long-acting or extended-release formulations than those attributed to non-ED settings (risk ratios ranged from 0.08 [0.07, 0.09] in the commercial population to 0.14 [95% CI 0.11, 0.17] in the aged Medicare population) ( Figure 2E ).
In all beneficiary populations, prescriptions attributed to the ED were less likely to progress to long-term opioid use. For beneficiaries treated in the ED, 1.1% of commercial beneficiaries, 3.1% of aged Medicare, and 6.2% of disabled Medicare progressed to long-term use (Table 2) . Commercial beneficiaries treated in the ED were 46% (adjusted risk ratio 0.54 [95% CI 0.53, 0.56]) less likely to progress to long-term use than commercial beneficiaries treated in non-ED settings. Aged Medicare beneficiaries were 56% (adjusted risk ratio 0.44 [95% CI 0.42, 0.46]) Figure 2F ). To determine whether guideline-concordant prescriptions were associated with a lower risk of progression to long-term use of opioids, we included a binary variable indicating whether the prescription met all guidelines in a regression of long-term use. Across nearly all care settings and beneficiary populations, a nonconcordant prescription was associated with a greater risk of progression to long-term opioid use (adjusted risk ratios range from 1 Table 3 for all risk ratios and confidence intervals.
In every year of the study, across all 3 populations and all measures of guideline concordance, prescriptions attributed to the non-ED setting were more likely to exceed guideline limits than those attributed to the ED.
The proportion of prescriptions exceeding 3 or 7 days and the proportion written for long-acting formulations were relatively stable during the study. However, the proportion of prescriptions written for large doses decreased from 2009 to 2011. In prescriptions exceeding 50 mg of morphine equivalents, this decrease ranged from 20% to 50%, depending on the treatment setting and beneficiary population. See Appendix E11, available online at http://www.annemergmed.com, for full details.
The proportion of prescriptions progressing to longterm opioid use decreased during the study period in all beneficiary populations and treatment settings. The largest decrease in progression to long-term use was in the aged Medicare population treated in the ED, from 2.1% in 2009 to 1.2% in 2015 (-42%); the smallest decrease was in the commercial population treated in non-ED settings, from 2.7% in 2009 to 2.4% in 2015 (-11%).
LIMITATIONS
A limitation of this study is the large number of prescriptions for which we were unable to assign a likely source. As noted, this issue has been found in a study using a different source of commercial claims. 33 We estimate that 7% to 10% of the prescriptions in this study were written by dentists, leaving 5% to 10% of the prescriptions unexplained. Further research is needed to clarify whether some of these prescriptions may indicate problematic prescribing practices in which a physician writes a prescription without seeing the patient. The data available in administrative claims did not allow us to attribute prescriptions to visits with complete certainty. Our method of attribution used the information available to assign a most likely source of prescriptions.
This study is limited to prescription fills submitted for insurance payment and to a population of commercial and Medicare Advantage beneficiaries. We did not include the uninsured or people with Medicaid or fee-for-service Medicare.
Given our study design, we were unable to evaluate whether the risk of long-term use was causally related to the Figure 2 . Risk ratios for outcomes by source of prescription. Risk ratios with non-ED prescription source as the reference category; bars indicate 95% CIs. Logistic regression with binary outcomes was performed, with independent variables representing beneficiary characteristics: beneficiary category (commercial, aged Medicare, disabled Medicare); year of fill (continuous); beneficiary age, age squared, and age cubed; indicators for each Elixhauser comorbidity and whether the beneficiary had any medical claims in the 6 months before the fill; female sex; and race/ethnicity. Adjusted proportions meeting each outcome were calculated for each beneficiary group with Stata's marginal effects commands. Risk ratios were calculated from these adjusted proportions, with 95% CIs calculated with Stata's nlcom command, which uses the delta method to produce standard errors. ER, Extended release; Com, commercial population; Mcr, Medicare; Disab., disabled. prescription's guideline concordance. Randomized controlled studies are unlikely to meet ethical guidelines for responsible research practice, given the weight of evidence on the risks of opioid use. The recent work of Barnett et al 19 suggested that observational studies of provider variability may be a source of quasi-random variation that could be used to study the effect of prescription characteristics on patient outcomes.
The CDC guidelines had not been released during the period we studied. Therefore, this study should not be understood as measuring physician adherence to the CDC guidelines, but rather as measuring physician practice in reference to evidence guiding best practices in prescribing.
DISCUSSION
Compared with that in non-ED settings, opioid prescriptions provided to opioid-naive patients in the ED were more likely to align with CDC recommendations for duration of these prescriptions for acute pain. More than 40% of prescriptions filled by disabled Medicare patients treated in non-ED settings exceeded 7 days' supply. In contrast, less than 5% of ED-attributed prescriptions exceeded 7 days in all 3 patient populations.
ED prescription durations in our study were similar to those in the study by Weiner et al, 40 which used Ohio Prescription Drug Monitoring Program data to study ED prescribing patterns from 2010 to 2014. Observations from this study showed rates of prescriptions exceeding 3 days that were similar to those found in the ED prescriptions in our study: 34% across their study period compared with 38% (commercial), 42% (aged Medicare), and 37% (disabled Medicare) in our study.
We expected a small number of prescriptions in excess of 50 or 90 mg of morphine equivalents to be issued to opioid-naive patients in any setting. These dose levels were selected by the CDC guideline writers as high doses for people with some degree of tolerance because of long-term opioid use. The high rates of prescriptions exceeding these levels were not anticipated. In non-ED settings, 1 in 6 prescriptions written for disabled Medicare patients and 1 in 5 for commercial patients were for more than 50 mg of morphine equivalents per day. The rates of prescriptions for more than 90 mg of morphine equivalents per day ranged up to 7% in the commercial population treated in non-ED settings. These high doses prescribed to people with no previous opioids in 6 or more months could be considered an indication that the individual had previously received opioids for a similar condition at a similar high dose. However, this may not be a safe practice for the majority of patients, in part because of the rapid resolution of opioid tolerance. 41, 42 As expected, we found low overall rates of prescriptions for long-acting and extended-release opioids. However, more than 2% of prescriptions written for the disabled Medicare population were for these formulations. This is a safety concern for opioid-naive patients because initiating opioid treatment with long-acting or extended-release formulations increases in the risk of overdose compared with immediate-release opioids. 43 The rate of continued use observed in this Medicare Advantage population is higher than that reported by Barnett et al, 19 who followed Medicare fee-for-service beneficiaries who were opioid naive in the previous 6 months and received an opioid prescription in the ED. They found that 1.2% to 1.5% of these patients progressed to long-term use, defined as 180 days supplied in 12 months after the initial prescription, but excluding the 30 days after the prescription. More than 3% of our Medicare Advantage beneficiaries treated in the ED progressed to long-term use; however, our definition of long-term use was not as strict as the definition used by Barnett et al 19 (120 days rather than 180 days in their study), and we did not exclude the 30 days after the prescription.
Although we did not set out to compare guideline concordance across beneficiary populations, we found that the disabled Medicare population was more likely to receive prescriptions exceeding 3 and 7 days, and was more likely to receive long-acting formulations compared with the aged Medicare and commercial populations. Future investigations comparing these populations are needed.
In conclusion, opioid prescriptions attributed to the ED for opioid-naive patients were more likely to adhere to best practices for opioid prescribing to opioid-naive patients compared with those attributed to non-ED settings. ED prescriptions were shorter in duration, written for lower doses, and less likely to be for long-acting or extendedrelease formulations. These prescriptions had a lower risk of progression to long-term opioid use.
Across all treatment settings and patient populations, guideline concordance was associated with a lower risk of long-term use. Among opioid-naive patients, greater guideline concordance in the ED may have been an important driver that helped mitigate the progression to long-term opioid use. Future research may explore why ED prescriptions for opioid-naive patients are more likely to be guideline concordant, with the hope of replicating that success in other settings in which opioid-naive patients are treated. Author contributions: MMJ, EPH, NDS, and MFB conceived and designed the study. MMJ drafted the article and managed and analyzed the data, including quality control and design of statistical analyses. All authors interpreted the data and contributed substantially to article revision, with critical revision for important intellectual content. MMJ takes responsibility for the paper as a whole.
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To limit the analysis to patients with an important risk of long-term opioid use, we excluded patients with active cancer diagnoses or hospice service use.
For the cancer population, we examined claims for evaluation and management services in the 3 months before the index opioid fill. We identified patients with at least 2 claims on separate days that included a cancer diagnosis. We used Elixhauser comorbidity diagnoses for metastatic cancer or for solid tumors without metastases. To identify patients receiving hospice services, we looked for at least one claim with either a hospice procedure code or a hospice revenue code in the 3 months before the index fill.
Procedure codes: 99377, 99378, G0182, G0337, G9474, G9475, G9476, G9477, G9478, G9479, G9524, Q5001, Q5002, Q5003, Q5004, Q5005, Q5006, Q5007, Q5008, Q5009, Q5010, S0255, S9126, T2042, T2043, T2044, T2045, T2046 opioid. We excluded DEA schedule 5 drugs (codeine cough syrups).
To limit the sample to drugs intended for home use, we excluded any injected or infused drug-those for which the dosage form was vial, syringe, ampule, cartridge, intravenous solution, etc.
We included only drugs that had a defined dose unit such as a tablet, pill, and milligrams per milliliter. This excluded drugs in powder or bulk form.
We included both single drug formulations and combinations of drugs. Table E1 includes all opioid drug combinations found in the table of NDC codes. Both longand short-acting formulations were included.
Buprenorphine, methadone, and drug combinations including naloxone may be used for both pain management and medication-assisted therapy for opioid use disorder. However, in an opioid-naive population, it is highly likely that these medications are being used for medicationassisted therapy. We excluded these drugs from the analysis of opioid-naive prescriptions. However, we did include them when determining whether a person was opioid naive and in calculating the risk of progression to long-term use. 
APPENDIX E4
Definition of an opioid fill An opioid fill was defined as a drug dispensed on a single day to an individual beneficiary by a single prescriber. Here, drug is defined by the opioid ingredient and formulation type: for example, all short-acting hydrocodone prescriptions filled on the same day with the same prescriber identification for the same individual would be counted as one fill. The total MME amount dispensed for each drug/person/prescriber combination is summed and divided by the maximum days' supply across the prescriptions. Examples:
Patient 1 has 2 fills on 1/1/2011: 1. 150 MME of SA hydrocodone with a day's supply of 10¼15 MME per day 2. 50 MME of LA hydrocodone with a day's supply of 5¼10 MME per day Patient 2 has 2 fills on 1/1/2011: 1. 50 MME of SA oxycodone with a day's supply of 5 from prescriber 10¼10 MME per day 2. 50 MME of SA oxycodone with a day's supply of 10 from prescriber 15¼5 MME per day
APPENDIX E5
Determining prescription source To determine the source of an opioid fill, we attempted to link a prescription claim to a medical claim representing the encounter in which the beneficiary received the prescription. Because opioids are scheduled drugs, we expect that in most cases, the prescriber will consult with the patient in person before writing the prescription. As of 2013, 41 states and Washington, DC, had state laws requiring physical examinations in relation to prescriptions for a controlled substance. 44 To find the visit that generated a prescription, we look for all medical claims in the 30 days before and including the date a prescription was filled. We used revenue and procedure codes identified by the National Committee for Quality Assurance to find inpatient, outpatient, and ED visits (except code 92888, used for physician consultation with emergency medical services). 45 We used revenue codes to identify ambulatory surgery services and Current Procedural Terminology codes to identify dental services. All other procedures and visits that were not classified as inpatient, outpatient, ED, ambulatory surgery, or dental services were captured and labeled "other" services. This category includes laboratory tests, imaging, physical therapy, and chiropractic care.
We identified inpatient, outpatient, ED, ambulatory surgery, or dental visit in the 30 days up to and including the index fill date. We attempted to match the provider identification for these visits to the prescriber identification on the pharmacy claim. If we found a matching visit, we assigned that visit as the most likely source of the prescription (N¼1,590,929; 30.3% of fills with any visit within 30 days). Because of limitations in the OLDW when the study was completed, we were unable to match prescriber identifications to medical claims physician identifications for Medicare Advantage beneficiaries.
If no visits were found with a provider identification matching the prescription, we assigned the most proximal visit as the source of the prescription. If no visits were found within 30 days of the index fill, but other services were present (for example, laboratory tests or imaging), we considered the prescription to have an unknown source. Of all prescriptions with a known source, 72% were filled on the same day as the visit, 85% within 3 days, and 90% within 1 week.
Once we identified the visit considered the most likely source of the fill, we classified the most likely source of each index fill as ED visit only; non-ED visit only, which combines inpatient, outpatient, ambulatory surgery, and dental/accidental dental; and unknown source. The unknown source category included both fills with no visit in the previous 30 days and fills in which the beneficiary had both an ED visit and a non-ED visit on the same day. A substantial proportion of prescriptions fall into the unknown source category: 26% for the commercial population and 15% to 16% for the Medicare population; most of these fills were classified as unknown because of having no visit in the previous 30 days. Another study using a different source of commercial claims found a similarly high rate of prescriptions that could not be matched to a visit: 28% unmatched with a look-back period of 2 weeks (vs 30 days for this study). 33 Some of these prescriptions were likely written by dentists, who have been estimated to write 6.4% of opioid prescriptions. 34 We did not observe most dental visits because dentistry is not included in medical insurance benefits. In our sample of fills to opioid-naive patients, 7.0% of fills with a known prescriber specialty were written by a dentist or other dental specialist. We present the results for prescriptions with unknown source throughout, but do not focus on the interpretation of this group of prescriptions. 
APPENDIX E7
Calculation of confidence intervals in Table 1 
APPENDIX E8
Complete logistic regression results for analyses presented in Table 2   Table E7 . Logistic regression results.
Odds Ratios Reported
Prescription Characteristics 
APPENDIX E9
Complete results for analysis of guideline concordance predicting long-term use 
APPENDIX E11
Supplementary analyses-time trends in guideline concordance and progression to long-term use To understand trends during the 7 years of our study period, we repeated the main analyses but included time as a categorical variable fully interacted with beneficiary population and treatment setting. We calculated marginal effects (predicted probability of exceeding 3 days, 7 days, 50 MME, 90 MME, of prescribing a long-acting formulation, and of progression to long-term opioid use) and graphed them by beneficiary population and time. We also included an "as observed" analysis showing the average across the entire population. Figure E1 . A, Probability of prescription greater than 3 days' supply. B, Probability of prescription greater than 7 days' supply. C, Probability of prescription greater than 50 MME per day. D, Probability of prescription greater than 90 MME per day. E, Probability of prescription for long-acting/extended release formulation. F, Probability of progression to long-term use. Table E13 . Probability of prescription greater than 90 mg of morphine equivalents per day, with 95% confidence intervals. Supplementary analyses-comparison of results when limiting analysis to beneficiaries with at least 1 year of follow-up Analyses of prescription guideline concordance by treatment setting included all qualifying prescriptions, regardless of the amount of follow-up time available for the beneficiary. Analysis of the risk of progression to long-term use was limited to patients with at least 1 year of follow-up, as required by the definition of long-term use (!120 days or !10 fills during 12 months). To determine whether the results of the guideline concordance analyses were affected by the difference in the population included, we repeated all guideline concordance analyses, limiting them to people with at least 1 year of follow-up.
We present the results as forest plots, one for each beneficiary population (commercial [ Figure E2 ], aged Medicare [ Figure E4 ], and disabled Medicare [ Figure E4] ). The risk ratios comparing the non-ED setting with the ED setting and the unknown setting are presented for each of the guideline concordance outcomes. The 1-year follow-up population is presented in red, whereas the population not limited by follow-up time is presented in blue. There were no statistically significant differences across the 2 populations. 
